Ularitide for the treatment of acute decompensated heart failure: From preclinical to clinical studies

European Heart Journal

Volumn 36, Issue 12, 2015, Pages 715-723

  Anker, Stefan D ^a   Ponikowski, Piotr ^b   Mitrovic, Veselin ^c   Peacock, W Frank ^d   Filippatos, Gerasimos ^e  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c KERCKHOFF HEART CENTER   (Germany)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute decompensated heart failure; Diuresis; Guanylate cyclase; Natriuresis; Ularitide; Vasodilation

Indexed keywords

URODILATIN; ATRIAL NATRIURETIC FACTOR; DIURETIC AGENT; PEPTIDE FRAGMENT;

ACUTE HEART FAILURE; CANINE MODEL; CROSS REACTION; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG URINE LEVEL; GLOMERULUS FILTRATION RATE; HEART STROKE VOLUME; HUMAN; NONHUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT MODEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SODIUM EXCRETION; SODIUM URINE LEVEL; VASCULAR RESISTANCE; WISTAR RAT; ACUTE DISEASE; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; FEMALE; HEART FAILURE; MALE; VASODILATATION;

ACUTE DISEASE; ANIMALS; ATRIAL NATRIURETIC FACTOR; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DIURETICS; FEMALE; HEART FAILURE; HUMANS; MALE; PEPTIDE FRAGMENTS; RATS, WISTAR; VASODILATION;

EID: 84931562954     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu484     Document Type: Review

References (41)

1. Forssmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol 1998;110:335-357.
2. Saba SR, Ramirez G, Vesely DL. Immunocytochemical localization of ProANF 1-30, ProANF 31-67, atrial natriuretic factor and urodilatin in the human kidney. Am J Nephrol 1993;13:85-93.
3. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66:752-759.
4. Goetz KL. Renal natriuretic peptide (urodilatin?) and atriopeptin: evolving concepts. Am J Physiol 1991;261(6 Pt 2):F921-F932.
5. Nagase M, Katafuchi T, Hirose S, Fujita T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens 1997;15:1235-1243.
6. Wilcox JN, Augustine A, Goeddel DV, Lowe DG. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991;11:3454-3462.
7. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 2009;14:309-319.
8. Carstens J, Jensen KT, Pedersen EB. Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci (Lond) 1997;92:397-407.
9. Fluge T, Fabel H, Wagner TO, Schneider B, Forssmann WG. Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Eur J Clin Invest 1995;25:728-736.
10. Mitrovic V, Luss H, Seferovic PM, Simeunovic D, Ristic AD, Felix S et al. Effects of ularitide on the endothelin and aldosterone system, cardiac troponins, and renal function in acute decompensated heart failure. Eur J Heart Fail 2013; 15(Suppl. 1):S10.
11. Goetz K, Drummer C, Zhu JL, Leadley R, Fiedler F, Gerzer R. Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J Am Soc Nephrol 1990;1:867-874.
12. + excretion. Am J Physiol 1992;262(3 Pt 2):F513-F516.
13. Meyer M, Richter R, Brunkhorst R, Wrenger E, Schulz-Knappe P, Kist A et al. Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am J Physiol 1996;271 (3 Pt 2):F489-F497.
14. Drummer C, Fiedler F, Konig A, Gerzer R. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J Am Soc Nephrol 1991;1:1109-1113.
15. Kentsch M, Kuhrmann T, Drummer C, Rodemerk U, Gerzer R, Muller-Esch G. [Renal urodilatin secretion is associated with diuresis and natriuresis after spontaneous, supraventricular tachycardia]. Z Kardiol 1998;87:134-138.
16. Drummer C, Kentsch M, Otter W, Heer M, Herten M, Gerzer R. Increased renal natriuretic peptide (urodilatin) excretion in heart failure patients. Eur J Med Res 1997;2:347-354.
17. Jovanovic A, Lehinant S, Forssmann WG, Hamm C, Mitrovic V. Plasma and urinary cGMP in heart failure in relation to natriuretic peptides (Abstract 949). Eur J Heart Fail Suppl 2010;9(Suppl 1):S168.
18. Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 2003;33:769-778.
19. Lenz W, Herten M, Gerzer R, Drummer C. Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line. Kidney Int 1999;55:91-99.
20. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 2000;97:8525-8529.
21. Drummer C, Fiedler F, Bub A, Kleefeld D, Dimitriades E, Gerzer R et al. Development and application of a urodilatin (CDD/ANP-95-126)-specific radioimmunoassay. Pflugers Arch 1993;423:372-377.
22. Herten M, Lenz W, Gerzer R, Drummer C. The renal natriuretic peptide urodilatin is present in human kidney. Nephrol Dial Transplant 1998;13:2529-2535.
23. Abassi ZA, Powell JR, Golomb E, Keiser HR. Renal and systemic effects of urodilatin in rats with high-output heart failure. Am J Physiol 1992;262(Pt 2):F615-F621.
24. Villarreal D, Freeman RH, Johnson RA. Renal effects of ANF (95-126), a new atrial peptide analogue, in dogs with experimental heart failure. Am J Hypertens 1991;4:508-515.
25. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JCJr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2005;288:R1093-R1097.
26. Riegger GA, Elsner D, Forssmann WG, Kromer EP. Effects of ANP-(95-126) in dogs before and after induction of heart failure. Am J Physiol 1990;259(Pt 2):H1643-H1648.
27. Gagelmann M, Hock D, Forssmann WG. Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126). FEBS Lett 1988;233:249-254.
28. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291(Pt 1):83-88.
29. Kentsch M, Ludwig D, Drummer C, Gerzer R, Muller-Esch G. Haemodynamic and renal effects of urodilatin in healthy volunteers. Eur J Clin Invest 1992; 22:319-325.
30. Kentsch M, Ludwig D, Drummer C, Gerzer R, Muller-Esch G. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 1992;22:662-669.
31. Elsner D, Muders F, Muntze A, Kromer EP, Forssmann WG, Riegger GA. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am Heart J 1995;129:766-773.
32. Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005; 150:1239.
33. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27:2823-2832.
34. Luss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008;155:1012-1018.
35. Publication Committee for the VMAC Investigators (Vasodilatation in theManagement of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
36. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
37. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-901.
38. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
39. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
40. Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014;35:431-441.
41. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-142.